La cadena de opciones muestra datos clave de las opciones de acciones de Natural Alternatives Intl a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Natural Alternatives Intl..

Natural Alternatives Intl (NASDAQ:NAII) Bolsa, Cadena de Opciones

Natural Alternatives Intl

Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.

Natural Alternatives International, Inc. ("NAI") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced the execution of an amended credit facility with Wells Fargo Bank, NA ("Wells Fargo"). This amendment modifies the current facility extending the term of the agreement to December 31, 2026 and modifies the borrowing capacity to $10 million.

News

NAII

Natural Alternatives Executes Amended Credit Facility With Wells Fargo Bank; Modifies Borrowing Capacity To $10M

Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) reported quarterly losses of $(0.37) per share. This is a 37.04 percent decrease over losses of $(0.27) per share from the same period last year. The company reported $28.77 million in sales this quarter. This is a 14.44 percent increase over sales of $25.14 million the same period last year.

Earnings

Natural Alternatives Intl Q3 EPS $(0.37) Down From $(0.27) YoY, Sales $28.77M Up From $25.14M YoY

Natural Alternatives International, Inc. (NAI) and CarnoSyn&#xAE; Brands today announced the publication of positive clinical trial results in the journal <a href="https://www.globenewswire.com/Tracker?data=wPGCrgCO8GfsXcN4HqFdTf5B3zF90RiE1i06Ei-uIVDYNl_32isGI6TLIE9fDM3Yb7zhnuE8-n8KzOELHS_kw8NiMO7K3gp58pc7nXDQdpOKt12QPRGoxT377bnYbJUcKPsQWDNf_Ltx63JId3-A_zD7z7jp_7gHw4MoK0lzo8U=">Food Hydrocolloids for Health</a> showing that TriBsyn&#x2122; supplementation led to significantly greater bioavailability and efficiency of beta-alanine along with the elimination of paresthesia, a common beta-alanine side effect.
Study Highlights:
<ul>
<li>TriBsyn&#x2122; is an encapsulated low-dose β-alanine complex.</li>
<li>TriBsyn&#x2122; increased plasma β-alanine 4.5-fold compared to conventional β-alanine.</li>
<li>TriBsyn&#x2122; achieved high plasma concentrations without the sensation of paresthesia. &nbsp;</li>
</ul>
TriBsyn&#x2122; is a carnosine booster derived from CarnoSyn&#xAE;&nbsp;beta-alanine and formulated using proprietary Hydro Oleo technology. This patent-pending formulation provides higher bioavailability and higher potency, enabling efficacious dosages at lower volumes while effectively eliminating paresthesia. The advanced formulation enables absorption through multiple pathways, including direct cellular uptake and traditional gastrointestinal routes, allowing for superior delivery at both the cellular and systemic levels. Adequate availability of beta-alanine is critical for maintaining muscle and promoting cognitive well-being. Efficacious doses of beta-alanine are often associated with harmless but generally uncomfortable symptoms of paresthesia, discouraging adherence to supplementation.
This study aimed to evaluate the bioavailability, pharmacokinetics, and tolerability of a 400 mg Hydro Oleo encapsulated beta-alanine complex (TriBsyn&#x2122;) specifically designed to reduce paresthesia. A randomized, double-blind, single-dose, three-treatment, three-way crossover oral bioavailability study was conducted in healthy older adults under fasting conditions. The study compared TriBsyn&#x2122; with low (400 mg) and high (1200 mg) doses of conventional beta-alanine. TriBsyn&#x2122; (400 mg) achieved a nearly 4.5-fold and 1.3-fold increase in circulating beta-alanine plasma concentrations compared to 400 mg and 1200 mg of conventional beta-alanine, respectively.
Using metrics such as the Visual Analogue Score (VAS) and Qualitative Light Symptoms Inventory (QLSI), sensory side effects were assessed. No paresthesia or adverse effects were reported in the TriBsyn&#x2122; group, while the conventional beta-alanine groups exhibited increasing paresthesia with dose. TriBsyn&#x2122; (400 mg beta-alanine) recorded a VAS score of 0.62 (indicating almost absent symptoms), whereas conventional β-alanine (400 mg) and conventional β-alanine (1200 mg) scored 2.02 and 4.01 respectively. These results highlight the reduced sensory discomfort in the TriBsyn&#x2122; group, despite its higher bioavailability.

Biotech

General

Natural Alternatives International And CarnoSyn Brands Publish Clinical Research Demonstrating TriBsyn Delivering Exceptional Bioavailability, Increased Efficiency And Paresthesia Elimination

Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) reported quarterly losses of $(0.33) per share. This is a 175 percent decrease over losses of $(0.12) per share from the same period last year. The company reported $33.15 million in sales this quarter. This is a 2.41 percent decrease over sales of $33.97 million the same period last year.

Natural Alternatives Intl Q1 EPS $(0.33) Down From $(0.12) YoY, Sales $33.15M Down From $33.97M YoY

Under the terms of the agreement, B&amp;D will distribute NAI&#39;s newly introduced carnosine booster, TriBsyn, to the U.S.-based nutritional dietary supplement, functional food, and beverage market segments.
Carnosine, which is naturally produced in the body through the synthesizing of beta-alanine and histidine, is a powerful antioxidant that has been shown to provide health benefits for muscle, brain, heart, bone, and overall systemic health.&nbsp;

NAI, CarnoSyn Brands Reveal New Distribution Partnership With B&D Nutritional Ingredients

<h3>Gainers</h3>
<ul>
<li>Paranovus Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVS#NASDAQ">PAVS</a>) stock rose 34.4% to $0.64 during Tuesday's regular session. The market value of their outstanding shares is at $43.4 million. </li>
<li>United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) stock moved upwards by 25.38% to $21.09. The market value of their outstanding shares is at $1.2 billion. The company's, Q4 earnings came out today. </li>
<li>Mangoceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRX#NASDAQ">MGRX</a>) shares increased by 20.0% to $0.28. The company's market cap stands at $8.4 million. </li>
<li>S&amp;W Seed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) stock rose 18.86% to $0.22. The market value of their outstanding shares is at $9.5 million. </li>
<li>Flora Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) shares rose 16.33% to $1.78. The market value of their outstanding shares is at $23.7 million. </li>
<li>Top Wealth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) stock rose 13.92% to $2.06. The market value of their outstanding shares is at $59.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Guardion Health Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHSI#NASDAQ">GHSI</a>) shares fell 42.6% to $3.18 during Tuesday's regular session. The market value of their outstanding shares is at $4.0 million. </li>
<li>Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) stock declined by 19.21% to $1.69. The market value of their outstanding shares is at $2.7 million. </li>
<li>Sadot Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) stock fell 12.74% to $0.37. The market value of their outstanding shares is at $17.0 million. </li>
<li>Big Tree Cloud Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) stock decreased by 12.5% to $4.2. The market value of their outstanding shares is at $239.7 million. </li>
<li>22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares declined by 11.58% to $0.19. The market value of their outstanding shares is at $4.0 million. </li>
<li>Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) stock decreased by 9.95% to $5.16. The company's market cap stands at $31.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-defensive-stocks/" title="www.benzinga.com/money/best-consumer-defensive-stocks/">www.benzinga.com/money/best-consumer-defensive-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BTTR

FLGC

GHSI

MGRX

PAVS

SANW

SDOT

UNFI

XXII

12 Consumer Staples Stocks Moving In Tuesday's Intraday Session

WIIM

Natural Alternatives International shares are trading lower after the company reported a year-over-year decrease in Q4 financial results.

Reported Earlier, Natural Alternatives Intl Q4 EPS $(0.32) Down From $0.35 YoY, Sales $29.49M Down From $35.89M YoY

Natural Alternatives International Launches TriBsyn, A New Carnosine Booster Utilizing CarnoSyn® Beta-Alanine And Patent-Pending Technology To Enhance Bioavailability And Absorption, Eliminating Paresthesia

Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) reported quarterly losses of $(0.27) per share. This is a 34.15 percent increase over losses of $(0.41) per share from the same period last year. The company reported $25.14 million in sales this quarter. This is a 23.13 percent decrease over sales of $32.70 million the same period last year.

Natural Alternatives Intl Q3 EPS $(0.27) Up From $(0.41) YoY, Sales $25.14M Down From $32.70M YoY

Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) reported quarterly losses of $(0.52) per share. This is a 267.74 percent decrease over earnings of $0.31 per share from the same period last year. The company reported $25.20 million in sales this quarter. This is a 40.42 percent decrease over sales of $42.30 million the same period last year.

Natural Alternatives Intl Q2 EPS $(0.52) Down From $0.31 YoY, Sales $25.20M Down From $42.30M YoY

Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) reported quarterly earnings of $0.35 per share. This is a 32.69 percent decrease over earnings of $0.52 per share from the same period last year. The company reported $35.89 million in sales this quarter. This is a 31.66 percent decrease over sales of $52.53 million the same period last year.

Natural Alternatives Intl Q4 EPS $0.35 Down From $0.52 YoY, Sales $35.89M Down From $52.53M YoY

<h3>Gainers</h3>
<ul>
<li>PhenomeX Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cell#NASDAQ">CELL</a>) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash transaction for $1 per share.</li>
<li>Tivic Health Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tivc#NASDAQ">TIVC</a>) shares jumped 39.1% to $0.0932. Tivic Health Systems shares jumped 80% on Wednesday after the company announced its funded study started enrollment for its non-invasive bioelectronic device approach to vagus nerve stimulation.</li>
<li>Sunlight Financial Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sunl#NYSE">SUNL</a>) climbed 36.9% to $0.2101 after declining 8% on Wednesday.</li>
<li>Advanced Health Intelligence Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahi#NASDAQ">AHI</a>) shares rose 30.2% to $5.00. Advanced Health Intelligence said it obtained overseas R&amp;D reimbursement under Australia&#39;s research and development tax incentive scheme.</li>
<li>Troika Media Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trka#NASDAQ">TRKA</a>) climbed 29% to $1.3794.</li>
<li>LSI Industries Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyts#NASDAQ">LYTS</a>) gained 21.8% to $15.55 following better-than-expected fourth-quarter results.</li>
<li>BioNexus Gene Lab Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bglc#NASDAQ">BGLC</a>) surged 22.2% to $0.88.</li>
<li>ETAO International Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etao#NASDAQ">ETAO</a>) rose 21% to $0.5600.</li>
<li>Ascent Solar Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asti#NASDAQ">ASTI</a>) gained 18.8% to $0.0799.</li>
<li>Super Group (SGHC) Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sghc#NASDAQ">SGHC</a>) jumped 18.7% to $3.4785 following strong quarterly results.</li>
<li>Catalyst Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cbio#NASDAQ">CBIO</a>) jumped 16.2% to $0.51.</li>
<li>Recruiter.com Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcrt#NASDAQ">RCRT</a>) gained 15.1% to $0.2139. Job Mobz announced plans to acquire iconic Recruiter.com brand in cash and stock deal.</li>
<li>Gambling.com Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gamb#NASDAQ">GAMB</a>) gained 14.3% to $14.51 as the company posted upbeat second-quarter results and raised FY23 guidance.</li>
<li>LQR House Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqr#NASDAQ">LQR</a>) surged 13.5% to $1.93.</li>
<li>Modular Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/modd#NASDAQ">MODD</a>) shares gained 13.2% to $1.1550 after the company announced a partnership with Phillips-Medisize to expand insulin delivery alternatives.</li>
<li>Datasea Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtss#NASDAQ">DTSS</a>) rose 10.3% to $0.59. Datasea announced a $4 million private placement priced at a 125% premium to market at $1.35 per share.</li>
<li>The Children&#39;s Place, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plce#NASDAQ">PLCE</a>) jumped 9.4% to $29.01. Children&#39;s Place reported a second-quarter FY23 sales decline of 9.3% year-on-year to $345.59 million, beating the analyst consensus of $342.64 million.</li>
<li>Avnet, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/avt#NYSE">AVT</a>) gained 9.6% to $49.28 following strong quarterly results.</li>
<li>Triumph Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgi#NYSE">TGI</a>) rose 8.1% to $9.04.</li>
<li>Knightscope, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kscp#NASDAQ">KSCP</a>) gained 6.8% to $1.2694 after falling 10% on Wednesday. The company recently posted upbeat quarterly results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Creative Realities, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crex#NASDAQ">CREX</a>) shares fell 35.6% to $1.9050 after the company reported pricing of $6 million public offering of 3 million shares of common stock at $2 per share.</li>
<li>EMCORE Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/emkr#NASDAQ">EMKR</a>) fell 35.6% to $0.4889 after the company reported pricing of $15.8 million public offering.</li>
<li>Tremor International Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trmr#NASDAQ">TRMR</a>) fell 29.6% to $4.41 after the company reported financial and operating results for the three and six months ended June 30, 2023.</li>
<li>China Liberal Education Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cleu#NASDAQ">CLEU</a>) fell 22.7% to $0.3363.</li>
<li>Amyris, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrs#NASDAQ">AMRS</a>) fell 21.3% to $0.0630.</li>
<li>Natural Alternatives International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/naii#NASDAQ">NAII</a>) fell 21.3% to $5.49. Natural Alternatives announced temporary closure of its new facility in Carlsbad, California.</li>
<li>Check-Cap Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chek#NASDAQ">CHEK</a>) fell 20.8% to $2.4374. Keystone Dental Holdings and Check-Cap entered into definitive business combination agreement.</li>
<li>KULR Technology Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kulr#NYSE">KULR</a>) shares tumbled 18.4% to $0.8811 after the company reported second-quarter financial results and announced a proposed public offering of common stock.</li>
<li>Wolfspeed, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wolf#NYSE">WOLF</a>) fell 18.4% to $43.40 after the company reported mixed fourth-quarter financial results and issued first-quarter adjusted EPS guidance below estimates.</li>
<li>G Medical Innovations Holdings Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmvd#NASDAQ">GMVD</a>) fell 18.2% to $0.1551.</li>
<li>Hawaiian Electric Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/he#NYSE">HE</a>) fell 17.7% to $11.70 following a report suggesting the company is facing multiple lawsuits alleging negligence over the Maui fires and is intalks with financial restructuring firms.</li>
<li>Novo Integrated Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvos#NASDAQ">NVOS</a>) declined 16.3% to $0.1516.</li>
<li>Akari Therapeutics, Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aktx#NASDAQ">AKTX</a>) fell 14.4% to $3.21.</li>
<li>Asure Software, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asur#NASDAQ">ASUR</a>) fell 14.2% to $11.89 after the company reported pricing of public offering of common stock.</li>
<li>AdaptHealth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahco#NASDAQ">AHCO</a>) fell 13.8% to $11.61.</li>
<li>UroGen Pharma Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/urgn#NASDAQ">URGN</a>) fell 12.9% to $18.70.</li>
<li>Calliditas Therapeutics AB (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calt#NASDAQ">CALT</a>) declined 11.5% to $16.36 following second-quarter results..</li>
<li>Gold Fields Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gfi#NYSE">GFI</a>) fell 11.4% to $11.27 as the company reported a decline in EPS for the half year.</li>
<li>CVS Health Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvs#NYSE">CVS</a>) declined 10.6% to $64.98 following reports that Blue Shield of California plans to drop CVS&#39;s Caremark as its pharmacy benefit manager.</li>
<li>Digital Brands Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dbgi#NASDAQ">DBGI</a>) fell 10.3% to $0.70 after jumping 91% on Wednesday.</li>
<li>NICE Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nice#NASDAQ">NICE</a>) fell 9.7% to $190.96 after the company reported second-quarter financial results and issued guidance.</li>
<li>Akumin Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aku#NASDAQ">AKU</a>) shares fell 9.5% to $0.1511 after jumping 22% on Wednesday.</li>
<li>Madison Square Garden Sports Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/msgs#NYSE">MSGS</a>) fell 7.1% to $190.99 following mixed fourth-quarter results and a decline in revenues.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/08/33895237/ethereum-tumbles-below-1-800-following-jobless-claims-data-sei-becomes-top-loser"> Ethereum Tumbles Below $1,800 Following Jobless Claims Data; Sei Becomes Top Loser</a>

Penny Stocks

Small Cap

Intraday Update

Markets

Trading Ideas

AHCO

AKTX

AMRS

ASTI

ASUR

BGLC

CALT

CBIO

CELL

CHEK

CLEU

CREX

DBGI

DTSS

EMKR

ETAO

GAMB

GMVD

KSCP

KULR

LYTS

MODD

MSGS

NICE

NVOS

PLCE

RCRT

SGHC

Sunlight Financial Holdings, Inc. Class A Common Stock

SUNL

TIVC

TRKA

TRMR

URGN

WOLF

Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

NAI has determined to temporarily close its new high-speed powder blending and packaging facility and has provided sixty days advance notice to most of the staff at that facility,&nbsp;who will be furloughed starting in
NAI has determined to temporarily close its new high-speed powder blending and packaging facility and has provided sixty days advance notice to most of the staff at that facility,&nbsp;who will be furloughed starting in early October and lasting until approximately&nbsp;December 31, 2023.Reduction of these anticipated orders and the closure of the facility is anticipated to have an adverse effect on our results of operations and financial condition primarily during the last calendar quarter of this year, and possibly into the early part of 2024.

Natural Alternatives Announces Temporary Closure Of Its New Facility In Carlsbad, California; Expects Action To Have An Adverse Effect On Results Of Operations

Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) reported quarterly losses of $(0.41) per share. This is a 200 percent decrease over earnings of $0.41 per share from the same period last year. The company reported $32.70 million in sales this quarter. This is a 22.83 percent decrease over sales of $42.37 million the same period last year.

Natural Alternatives Intl Q3 EPS $(0.41) Down From $0.41 YoY, Sales $32.70M Down From $42.37M YoY

<h3>What Defines a Value Stock?</h3>
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. 
<h2>Below is a list of notable value stocks in the consumer defensive sector:</h2>
<ol>
<li>Skillsoft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKIL#NYSE">SKIL</a>) - P/E: 1.54</li>
<li>Herbalife Nutrition (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) - P/E: 4.58</li>
<li>Tarena International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEDU#NASDAQ">TEDU</a>) - P/E: 3.31</li>
<li>Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) - P/E: 6.36</li>
<li>Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) - P/E: 9.23</li>
</ol>
Skillsoft saw a decrease in earnings per share from -0.19 in Q3 to $-0.21 now. Herbalife Nutrition saw a decrease in earnings per share from 0.91 in Q3 to $0.53 now. The company's most recent dividend yield sits at 1.71%, which has decreased by 1.82% from 3.53% last quarter. 
Tarena International's earnings per share for Q4 sits at $-0.18, whereas in Q3, they were at 0.45. The company's most recent dividend yield sits at 0.0%, which has decreased by 4.32% from 4.32% last quarter. 
Natural Alternatives Intl saw an increase in earnings per share from 0.18 in Q1 to $0.31 now. Albertsons Companies has reported Q4 earnings per share at $0.79, which has decreased by 9.2% compared to Q3, which was 0.87. Its most recent dividend yield is at 2.26%, which has decreased by 0.03% from 2.29% in the previous quarter.
These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

SKIL

TEDU

A Look Into Consumer Defensive Sector Value Stocks

<h3>What is a Value Stock?</h3>
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. 
<h2>Below is a list of notable value stocks in the consumer defensive sector:</h2>
<ol>
<li>Bunge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) - P/E: 9.07</li>
<li>Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) - P/E: 6.27</li>
<li>Industrias Bachoco SAB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBA#NYSE">IBA</a>) - P/E: 9.18</li>
<li>Ingles Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMKTA#NASDAQ">IMKTA</a>) - P/E: 6.01</li>
<li>Tarena International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEDU#NASDAQ">TEDU</a>) - P/E: 2.95</li>
</ol>
This quarter, Bunge experienced a decrease in earnings per share, which was $3.45 in Q3 and is now $3.24. Most recently, the company reported a dividend yield of 2.6%, which has increased by 0.14% from last quarter's yield of 2.46%.
Natural Alternatives Intl has reported Q2 earnings per share at $0.31, which has increased by 72.22% compared to Q1, which was 0.18. Industrias Bachoco SAB has reported Q4 earnings per share at $0.08, which has decreased by 91.75% compared to Q3, which was 0.97. The company's most recent dividend yield sits at 2.28%, which has increased by 0.23% from 2.05% last quarter. 
This quarter, Ingles Markets experienced a decrease in earnings per share, which was $3.69 in Q4 and is now $3.65. The company's most recent dividend yield sits at 0.75%, which has increased by 0.08% from 0.67% last quarter. 
Tarena International saw a decrease in earnings per share from 0.45 in Q3 to $-0.18 now. The company's most recent dividend yield sits at 0.0%, which has decreased by 4.32% from 4.32% last quarter. 
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

IMKTA

Overview Of Value Stocks In The Consumer Defensive Sector

Natural Alternatives International, Inc. (&quot;NAI&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>), an international leader in custom contract nutritional supplement manufacturing for over four decades, today announced that new research on the cognitive benefits of SR CarnoSyn&reg;&nbsp;beta-alanine tablets, a patented sustained release delivery system owned by NAI, has been published in&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3791010-1&amp;h=2401778467&amp;u=https%3A%2F%2Fwww.mdpi.com%2F2072-6643%2F15%2F4%2F923&amp;a=Nutrients" target="_blank">Nutrients</a>.
Natural Alternatives International announces new research on the cognitive benefits of SR CarnoSyn&reg; beta-alanine tablets
The benefits of CarnoSyn&reg;&nbsp;Brands&#39; beta-alanine supplementation on functional performance in older adults has been reported in several prior clinical studies. These human studies have demonstrated that supplementing with CarnoSyn&reg;&nbsp;beta-alanine can delay fatigue, increase strength, and improve functional performance. Various clinical studies concluded that CarnoSyn&reg;&nbsp;beta-alanine supplementation is associated with improved executive function and that the anti-inflammatory and antioxidant effects of increased tissue carnosine levels supports improved health in older adults.
This new clinical study provided the biggest scale of participants with precise experimental designs, showing SR CarnoSyn&reg;&nbsp;beta-alanine supplementation benefits cognitive function in sedentary older adults. This clinical study is also the first conducted with a 600 milligram SR CarnoSyn&reg;&nbsp;beta-alanine tablet providing 2.4 grams of daily supplementation. The study results indicated improved cognitive function in older adults whose cognitive function at baseline was at or below normal. In addition, results indicated significant depression score reductions using the Geriatric Depression Scale (GDS).
The study included one hundred older adults between the ages of 60-80 who volunteered to participate in this double-blind, randomized controlled study. Any participant who had underlying neurological conditions was not eligible to enroll in the study. All interviews were conducted by a licensed physician. Participants were not permitted to use any additional nutritional supplements for at least six weeks prior to the study.
Before taking their first supplement, participants completed several tests consisting of written questionnaires to assess cognitive function and mood, and a computer-based exam to measure cognitive and executive function. In addition, a series of physical function tests were performed.
Testing occurred prior to supplementation, at the midpoint, and at week ten. Participants were instructed to consume two 600 mg tablets twice per day for the duration of the ten-week study. The SR CarnoSyn&reg;&nbsp;beta-alanine supplement and the placebo were identical in appearance.
Cognitive and mood measures consisted of cognitive function assessments, including the Montreal Cognitive Assessment (MoCA), the Stroop pattern recognition test, and the Profile of Mood States (POMS). In addition, participants were also asked to complete the Geriatric Depression Scale (GDS) and the Geriatric Anxiety Scale (GAS).
&quot;CarnoSyn&reg;&nbsp;Brands has been devoted to science-based ingredients and products for over 15 years,&quot; said&nbsp;Aaron Starr, Vice President, CarnoSyn&reg;&nbsp;Brands. &quot;We were very excited to sponsor this clinical study with such a prestigious institution and research team. This was a well-crafted and executed clinical study, especially considering the difficulties of recruiting participants and conducting this study during the pandemic. The positive study results help bolster our existing and extensive CarnoSyn&reg;&nbsp;research and provides additional scientific evidence of the benefits of CarnoSyn&reg;&nbsp;beta-alanine to help further educate our customers and consumers.&quot;
SR CarnoSyn&reg;&nbsp;has six research studies showing brain health and mood improvement, with numerous benefits for users:
<ul>
<li>Improves executive functioning, mental clarity and enhances cognitive process.</li>
<li>Reduces mental fatigue.</li>
<li>Supports brain health, cognitive function, and memory.</li>
<li>Studies show improved attention and task focus in adults.</li>
<li>Helps boost mental clarity, concentration, and alertness.</li>
<li>Promotes a healthy response to everyday stress.</li>
<li>Fosters a more balanced mood and supports a sense of calm.</li>
</ul>
About CarnoSyn&reg;&nbsp;Brands:
CarnoSyn&reg;&nbsp;Brands feature two clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn&reg;&nbsp;instant release beta-alanine powder and SR CarnoSyn&reg;&nbsp;sustained release beta-alanine tablets. In 2019, CarnoSyn&reg;&nbsp;beta-alanine successfully obtained NDI status from the FDA and received Self-Affirmed GRAS (Generally Recognized as Safe) status. SR CarnoSyn&reg;, an advanced delivery form of CarnoSyn&reg;, received GRAS affirmation in 2017. The GRAS affirmation allows NAI to broaden their product offerings within the food and beverage industries, including medical and other fortified food products.

Newly Published Study Shows Sr Carnosyn Beta-Alanine Improves Cognitive Function In Older Adults

<h3>Understanding Value Stocks</h3>
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. 
<h2>Below is a list of notable value stocks in the consumer defensive sector:</h2>
<ol>
<li>Post Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) - P/E: 8.01</li>
<li>Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) - P/E: 7.3</li>
<li>Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) - P/E: 6.41</li>
<li>Herbalife Nutrition (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) - P/E: 5.94</li>
<li>Ingles Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMKTA#NASDAQ">IMKTA</a>) - P/E: 6.49</li>
</ol>
Post Hldgs's earnings per share for Q1 sits at $1.08, whereas in Q4, they were at 0.85. Its most recent dividend yield is at 6.43%, which has increased by 0.76% from 5.67% in the previous quarter.
Tyson Foods's earnings per share for Q4 sits at $1.63, whereas in Q3, they were at 1.94. Most recently, the company reported a dividend yield of 2.89%, which has increased by 0.47% from last quarter's yield of 2.42%.
Natural Alternatives Intl has reported Q1 earnings per share at $0.18, which has decreased by 65.38% compared to Q4, which was 0.52. Most recently, Herbalife Nutrition reported earnings per share at $0.91, whereas in Q2 earnings per share sat at $0.96. Most recently, the company reported a dividend yield of 1.71%, which has decreased by 1.82% from last quarter's yield of 3.53%.
Most recently, Ingles Markets reported earnings per share at $3.65, whereas in Q4 earnings per share sat at $3.69. The company's most recent dividend yield sits at 0.67%, which has decreased by 0.14% from 0.81% last quarter. 
These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

POST

Natural Alternatives International, Inc. (&quot;NAI&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced its Board of Directors authorized a&nbsp;$1.0 million&nbsp;increase to its stock repurchase plan bringing the total plan authorized repurchase amount to&nbsp;$19.0 million. Under the repurchase plan, NAI may, from time to time, purchase shares of its common stock, depending upon market conditions, in open market or privately negotiated transactions. To date, we have purchased 2.1 million shares under this repurchase plan and after this increase we will have&nbsp;$1.2 million&nbsp;available for future stock repurchases under the plan.
Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, &quot;We believe our stock continues to trade at levels significantly below the fair value of our company and we have increased our buyback authority to allow us to continue to purchase our shares. Our management team remains confident in our long-term success and the growth potential of our business. We are committed to expanding our business through growth in sales and we are excited that our new manufacturing and warehouse facility in&nbsp;Carlsbad, CA&nbsp;will become operational early in the new calendar year.&quot;
NAI, headquartered in&nbsp;Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3728428-1&amp;h=682126173&amp;u=http%3A%2F%2Fwww.nai-online.com%2F&amp;a=http%3A%2F%2Fwww.nai-online.com" target="_blank">http://www.nai-online.com</a>.
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, the fair value of our company, the growth potential of our business, our ability to acquire our shares on a reasonable basis, development of our new manufacturing and warehouse facility, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI&#39;s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

Buybacks

Natural Alternatives International Announces A $1M Increase In Its Stock Repurchase Plan, Bringing The Total Plan Authorized Repurchase Amount To $19M

Restaurants

Press Releases

CarnoSyn® Brands Unveils TriBsyn™ - "The World's First Paresthesia-Free Beta-Alanine Powder"

CarnoSyn® Brands Showcasing TriBsyn™ at the 46th ESPEN Congress On Clinical Nutrition & Metabolism

Natural Alternatives International, Inc. Announces Fiscal 2024 Q4 and YTD Results

CarnoSyn® Brands Announces New U.S. Distribution Agreement With B&D Nutritional Ingredients

Natural Alternatives International, Inc. Announces 2025 Q1 Results

Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results

Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn™ Delivering Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination

Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results

Financing

Natural Alternatives International, Inc. Announces Amended and Extended Credit Facility with Wells Fargo Bank

Comments

Natural Alternatives Intl

Natural Alternatives Intl (NAII) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL